Biocon, Zentiva get nod for Liraglutide in European Union

24 Dec 2024 Evaluate

Biocon and its European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

326.75 10.20 (3.22%)
15-Apr-2025 10:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1710.55
Dr. Reddys Lab 1141.00
Cipla 1468.05
Lupin 2003.25
Zydus Lifesciences 871.75
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...